The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal
Abstract
BACKGROUND: Opioid overdose is a leading cause of accidental death in the United States. OBJECTIVE: To estimate the cost-effectiveness of distributing naloxone, an opioid antagonist, to heroin users for use at witnessed overdoses. DESIGN: Integrated Markov and decision analytic model using deterministic and probabilistic analyses and incorporating recurrent overdoses and a secondary analysis assuming heroin users are a net cost to society. DATA SOURCES: Published literature calibrated to epidemiologic data. TARGET POPULATION: Hypothetical 21-year-old novice U.S. heroin user and more experienced users with scenario analyses. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Naloxone distribution for lay administration. OUTCOME MEASURES: Overdose deaths prevented and incremental cost-effectiveness ratio (ICER). RESULTS OF BASE-CASE ANALYSIS: In the probabilistic analysis, 6% of overdose deaths were prevented with naloxone distribution; 1 death was prevented for every 227 naloxone kits distributed (95% CI, 71 to 716). Naloxone distribution increased costs by $53 (CI, $3 to $156) and quality-adjusted life-years by 0.119 (CI, 0.017 to 0.378) for an ICER of $438 (CI, $48 to $1706). RESULTS OF SENSITIVITY ANALYSIS: Naloxone distribution was cost-effective in all deterministic and probabilistic sensitivity and scenario analyses, and it was cost-saving if it resulted in fewer overdoses or emergency medical service activations. In a "worst-case scenario" where overdose was rarely witnessed and naloxone was rarely used, minimally effective, and expensive, the ICER was $14 000. If national drug-related expenditures were applied to heroin users, the ICER was $2429. LIMITATION: Limited sources of controlled data resulted in wide CIs. CONCLUSION: Naloxone distribution to heroin users is likely to reduce overdose deaths and is cost-effective, even under markedly conservative assumptions. PRIMARY FUNDING SOURCE: National Institute of Allergy and Infectious Diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Decision Modelling For Health Economic Evaluation
Briggs, A., Claxton, K., & Sculpher, M. (2006) · doi:10.1093/oso/9780198526629.001.0001 · Cited by 3,153
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
Paulozzi, L. J., Jones, C. M., Mack, K. A., & Rudd, R. A. (2011) · PubMed · Cited by 1,529
Representing uncertainty: the role of cost‐effectiveness acceptability curves
Fenwick, E., Claxton, K., & Sculpher, M. (2001) · Health Economics · doi:10.1002/hec.635 · Cited by 1,110
A 33-Year Follow-up of Narcotics Addicts
Hser, Y.-I., Hoffman, V., Grella, C. E., & Anglin, M. D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.503 · Cited by 848
Larimer, M. E. (2009) · JAMA · doi:10.1001/jama.2009.414 · Cited by 615
Sporer, K. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-7-199904060-00019 · Cited by 342
Vlahov, D., US Department of Health and Human Services; National Institute on Drug Abuse, Anthony, J. C., Munoz, A., Margolick, J., Nelson, K. E., Celentano, D. D., Solomon, L., & Polk, B. F. (1991) · PsycEXTRA Dataset · doi:10.1037/e496262006-006 · Cited by 336
Coffin, P. O., Galea, S., Ahern, J., Leon, A. C., Vlahov, D., & Tardiff, K. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00376.x · Cited by 334
Self-citationOverdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non‐fatal overdose
DARKE, S., ROSS, J., & HALL, W. (1996) · Addiction · doi:10.1046/j.1360-0443.1996.9134059.x · Cited by 302
Community-Based Opioid Overdose Prevention Programs Providing Naloxone —United States, 2010
(2012) · JAMA · doi:10.1001/jama.307.13.1358 · Cited by 257
Cited by
Relationship between Nonmedical Prescription-Opioid Use and Heroin Use
Compton, W. M., Jones, C. M., & Baldwin, G. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1508490 · Cited by 1,044
Estimating the Attributable Cost of Physician Burnout in the United States
Han, S., Shanafelt, T. D., Sinsky, C. A., Awad, K. M., Dyrbye, L. N., Fiscus, L. C., Trockel, M., & Goh, J. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1422 · Cited by 928
U.S. Department of Health and Human (2015) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2015.1037530 · Cited by 891
McDonald, R., & Strang, J. (2016) · Addiction · doi:10.1111/add.13326 · Cited by 471
Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014.
(2015) · PubMed Central · Cited by 426
Metadata
- Authors
- Coffin, P. O., & Sullivan, S. D.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2013-01-01
- Volume
- 158
- Issue
- 1
- Pages
- 1-9
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1979466410
- Cited by
- 343
- References
- 63
- FWCI
- 31.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal. https://app.cochat.ai/papers/10.7326/0003-4819-158-1-201301010-00003
- The paper
- Coffin, P. O., & Sullivan, S. D. (2013). Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-158-1-201301010-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.